Skip to content
naulon

Not checkedNot checked for notices yet.

News in brief

Jack Williamson

The Lancet. Healthy Longevity · 2021

doi:10.1016/s2666-7568(21)00011-8 (opens in a new tab)

We email you when a new notice or a question about this paper appears.

Abstract

The clinical value of convalescent plasma for treating patients with COVID-19 has been a key question of concern. Previously tested on patients who were moderately or severely ill with the disease, convalescent plasma provided only weak evidence of clinical efficacy. Another strategy, suggested by the Emergency Use Authorization, is to use high-titer convalescent plasma in patients shortly after onset of symptoms. In a multicentre, randomised controlled trial, Romina Libster (Fundación Infant, Buenos Aires, Argentina) and colleagues investigated 250 ml of convalescent plasma (with IgG titer >1:1000 against severe acute respiratory syndrome coronavirus 2 spike protein) versus placebo in 160 patients (mean age 77 years, including patients with coexisting conditions) within 72 h after the onset of mild COVID-19 symptoms.

Abstract licence: CC BY-NC

Reads

Read by people on this page

None yet.

Checked or read by AI through naulon

None yet.

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.

Are you an author?

Is this your paper?

Claim it to add your note and be paid when agents cite it. Free.